Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2011

May 26, 2011

30583_dirs_2011-05-26_9532708a-1f46-496a-99fa-b77921bef613.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2011-05-25

Reporting Person: ASELAGE STEVE (EVP, Chief Business Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-05-25 Common Stock M 9177 $17.33 Acquired 53155 Direct
2011-05-25 Common Stock S 9177 $27.00 Disposed 43978 Direct
2011-05-26 Common Stock M 40512 $17.33 Acquired 84490 Direct
2011-05-26 Common Stock S 40512 $27.0001 Disposed 43978 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-05-25 Stock Option (right to buy) $17.33 M 9177 Disposed 2017-06-06 Common Stock (9177) Direct
2011-05-26 Stock Option (right to buy) $17.33 M 40512 Disposed 2017-06-06 Common Stock (40512) Direct

Footnotes

F1: The price in Column 4 is a weighted average price. The prices actually received range from $27.00 to $27.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2: Original option vests 6/48ths on December 7, 2007 and 1/48th on the 7th of every month thereafter.